【摘要】 目的:观察21例经肝动脉化疗联合拉米夫定治疗的乙型肝炎病毒(HBV)相关性肝癌病人肝功能变化。方法:对经肝动脉化疗的HBV相关性肝癌病人,根据是否口服拉米夫定分为两组,治疗组:12例经肝动脉化疗和口服拉米夫定治疗,对照组:9例仅经肝动脉化疗,未口服拉米夫定治疗。结果:治疗组HBV-DNA水平明显降低,拉米夫定没有引发YMDD及核心启动子区突变。虽然治疗组ALT、TSB、PT前后没有改变,但是对照组的ALT、TSB却出现升高、PT延长。结论:拉米夫定治疗可降低HBV-DNA水平,并能防治乙型肝炎病毒阳性的肝癌病人在化疗过程中肝损害的加重。更多还原

【Abstract】 Objective:To observe the efficacy of lamivudine for protecting live function before and after the treatment.Methods:21 patients were divided randomly into two groups:control group,which is treated with trans-hepatic arterial chemo-embolization(TACE);treatment group,which is treated with TACE as well as oral lamivudine.The level of ALT,AST,ALB,PT and AFP were measured at the begining and after the end of four weeks.Results:Liver function of the treatment group was not changed after treatment while that of the control group increased compared with before treatment.Conclusion:Oral lamivudine contributes to reduce HBVDNA and protect the liv-er from chemotherapy.更多还原